0001593968-23-000345.txt : 20230223
0001593968-23-000345.hdr.sgml : 20230223
20230223163723
ACCESSION NUMBER: 0001593968-23-000345
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230221
FILED AS OF DATE: 20230223
DATE AS OF CHANGE: 20230223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ignelzi Troy A.
CENTRAL INDEX KEY: 0001579829
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 23660311
MAIL ADDRESS:
STREET 1: C/O ESPERION THERAPEUTICS, INC.
STREET 2: 46701 COMMERCE CENTER DRIVE
CITY: PLYMOUTH
STATE: MI
ZIP: 48170
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
primary_01.xml
PRIMARY DOCUMENT
X0306
4
2023-02-21
0001771917
Karuna Therapeutics, Inc.
KRTX
0001579829
Ignelzi Troy A.
C/O KARUNA THERAPEUTICS, INC.
99 HIGH STREET, 26TH FLOOR
BOSTON
MA
02110
false
true
false
false
Chief Financial Officer
Common Stock
2023-02-21
4
M
false
6000
9.2
A
36487
D
Common Stock
2023-02-21
4
S
false
6000
190.01
D
30487
D
Option (right to buy)
9.20
2023-02-21
4
M
false
6000
0
D
2029-03-21
Common Stock
6000
103726
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.96 to $190.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.
/s/ Troy Ignelzi
2023-02-23